当前位置: X-MOL 学术Int. J. STD AIDS › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL).
International Journal of STD & AIDS ( IF 1.4 ) Pub Date : 2023-11-16 , DOI: 10.1177/09564624231215977
Charlotte O'Halloran 1 , Yvonne Gilleece 2 , Suki Leung 3 , Veronica Canuto 3 , Connor McAlpine 4 , Sophie Ross 2 , Claire Norcross 2 , Stuart Gaffney 1 , Nipur Siani 1 , William Hickey 1 , Adam Moore 5 , Olivera Rajkovic-Hooley 5 , Ana Milinkovic 3, 6
Affiliation  

BACKGROUND Doravirine is a non-nucleoside reverse transcriptase inhibitor recommended for the treatment of virologically suppressed and treatment naïve people living with HIV. The DRIVE-REAL study aimed to describe the characteristics, treatment patterns, and virological outcomes of doravirine users in a real-world cohort in the UK. METHODS A retrospective, observational, multi-centre chart review was conducted for 300 adults living with HIV initiating doravirine-containing antiretroviral therapy. RESULTS At baseline 83% of individuals were male, 45% aged ≥50 years, 65% white ethnicity. Median time since HIV diagnosis was 12 years. 96% were antiretroviral therapy-experienced, 87% had a HIV viral load <50 copies/ml, and 15% had resistance to at least one antiretroviral drug. 66% had comorbidities, most commonly depression (26%), and 70% were taking at least one co-medication. At six months, 94% (n = 283/300) were still receiving doravirine. Viral load data were available for n = 266/300 individuals and 95% (n = 253/266) had viral load <50 copies/ml. CONCLUSIONS Individuals initiating doravirine in this cohort are predominantly treatment-experienced white middle-aged males, with a high frequency of comorbidities and co-medication. The majority of individuals at 6 months remained on doravirine and maintained or achieved HIV viral suppression. This study provides epidemiologic characteristics that can inform clinical care and subsequent hypothesis-testing studies.

中文翻译:

英国人类免疫缺陷病毒感染者中多拉韦林的真实使用情况 (DRIVE-REAL)。

背景多拉韦林是一种非核苷类逆转录酶抑制剂,推荐用于治疗病毒学受到抑制和未接受过治疗的 HIV 感染者。DRIVE-REAL 研究旨在描述英国现实世界队列中多拉韦林使用者的特征、治疗模式和病毒学结果。方法 对 300 名开始接受含多拉韦林抗逆转录病毒治疗的 HIV 感染者进行了回顾性、观察性、多中心图表审查。结果 基线时,83% 的人为男性,45% 的人年龄≥50 岁,65% 的人为白人。自 HIV 诊断以来的中位时间为 12 年。96% 的人接受过抗逆转录病毒治疗,87% 的人 HIV 病毒载量<50 拷贝/ml,15% 的人对至少一种抗逆转录病毒药物有耐药性。66% 的人患有合并症,最常见的是抑郁症 (26%),70% 的人至少服用一种联合药物。六个月时,94% (n = 283/300) 仍在接受多拉韦林治疗。n = 266/300 人的病毒载量数据可用,其中 95% (n = 253/266) 的病毒载量<50 拷贝/ml。结论 该队列中开始使用多拉韦林的个体主要是有治疗经验的白人中年男性,合并症和联合用药的频率很高。大多数人在 6 个月时仍继续服用多拉韦林并维持或实现了 HIV 病毒抑制。这项研究提供了流行病学特征,可以为临床护理和随后的假设检验研究提供信息。
更新日期:2023-11-16
down
wechat
bug